World Stroke Day - SVIN latest clinical trials and breaking science news

The Society of Vascular and Interventional Neurology (SVIN) would like to announce today on World Stroke Day that it stands committed to the advancement of scientific research to improve the lives of stroke (aka brain-attack) patients worldwide. Stroke and interventional neurologists, who are members of the SVIN, working collaboratively with interventional neuro-radiologists and endovascular neurosurgeons have played a pivotal role in clinical trials pioneering the use of clot retrieval devices, such as retrievable stents and vacuum aspiration devices, also referred to as stroke thrombectomy.

"This collaborative effort, with stroke surgeons worldwide, has led to the establishment of stroke thrombectomy as a standard of care for large vessel occlusion (LVO) stroke." explains Italo Linfante, MD FAHA FSVIN, current President of the SVIN. "We are at a very exciting phase in brain-attack care similar to heart-attack care in the mid-90's. The results of the latest clinical trials and breaking news on next-generation devices that can transform stroke thrombectomy in the next decade, will be among the key highlights at our upcoming annual meeting." summarizes Dr. Linfante.

In the past year, there have been two randomized clinical trials (ASTER and COMPASS) evaluating the role of vacuum aspiration for removing blood clots in LVO stroke patients. In addition, there have been two randomized clinical trials evaluating the role of stroke thrombectomy in extended treatment time windows (DAWN: within 6-24 hours and DEFUSE 3: within 6-16 hours of stroke onset) to benefit LVO stroke patients including those who wake up with a stroke.

"We are pleased to announce that the results of another landmark clinical trial for stroke thrombectomy, namely the POSITIVE Stroke Clinical Trial will be presented at the upcoming SVIN annual meeting." reiterates Ameer E. Hassan, DO FAHA FSVIN, Chair of SVIN's 2018 annual meeting. Lead authors Drs. J Mocco and Aquilla Turk, along with their POSITIVE trial collaborators will be presenting the results of the POSITIVE (PerfusiOn Imaging Selection of Ischemic STroke PatIents for EndoVascular ThErapy) Stroke Clinical Trial (ClinicalTrials.gov NCT01852201). This is a randomized clinical trial comparing endovascular treatment (stroke thrombectomy with vacuum aspiration or a retrievable stent, separately or in combination) versus best medical therapy in LVO stroke patients with appropriate imaging selection within 6-12 hours of stroke onset.

A panel of leading stroke experts rigorously reviewed over 150 scientific research submissions to select the latest clinical trials and breakthrough technology to be showcased at the SVIN's 2018 annual meeting. Thanh Nguyen, MD FRCPc FAHA FSVIN, Chair of SVIN's scientific research committee explains, "In addition to the latest clinical trials, we want to showcase the groundbreaking science behind the most innovative devices that have tremendous potential to improve stroke thrombectomy worldwide."

One such news is from lead authors Drs. Miklos Marosfoi and Matthew J. Gounis, who along with their collaborators at the University of Massachusetts, will be presenting foundational research on a new aspiration device platform that can offer cyclical vacuum aspiration (varying the vacuum suction intensity) as a means of improving clot ingestion into aspiration catheters. In addition, they will be presenting the role of cyclical vacuum aspiration in decreasing release of dangerous debris during stroke thrombectomy that could cause secondary stroke.

The SVIN 2018 Annual Meeting will be held November 14-17 in San Diego, California. "We are excited that stroke surgeons, clinical trialists, and innovators worldwide are choosing the SVIN annual meeting forum to present the results of the latest clinical trials and breaking news on next-generation technologies that can have a transformative impact on stroke thrombectomy and thereby improving the lives of stroke patients and their caregivers worldwide." concludes Dr. Linfante.

About SVIN

The Society of Vascular and Interventional Neurology was created to achieve the highest level of care for patients through increased collaboration in scientific research and by educating young professionals and training young investigators. The Society also aims to provide opportunities to connect leaders in the field and provide a common ground for dialogue and creation of practice and safety standards. Our mission is to represent the advancement of interventional neurology as a field with the ultimate goal of improving clinical care and outcomes of patients with stroke and cerebrovascular diseases.

The SVIN Annual Meeting is a premier academic venue with scientific presentations covering the full spectrum of cerebrovascular diseases and stroke. Participants have the opportunity to discuss embolectomy, aneurysms and AVMs, subarachnoid and intracranial hemorrhage, endovascular saves and innovative approaches, new device review, international perspectives, and other-related topics. The SVIN 2018 Annual Meeting will be held November 14-17 in San Diego, California. New for 2018, SVIN is pleased to announce a vascular neurology track, an advance practice provider track, a live Basic Stroke Emergency Support course, and a hands on fellows training course. Registration for the SVIN 2018 Annual Meeting is now open.

For further information about SVIN, please visit http://www.svin.org

Most Popular Now

Top 20 breaking World Pharma News of 2018

World Pharma News proudly presents the top 20 most popular breaking news from 2018. Have a wonderful 2019 New(s) Year filled with health, happiness, and spectacular succe...

Bristol-Myers Squibb to acquire Celgene to create …

Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristo...

Lynparza meets primary endpoint in Phase III SOLO-…

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced positive results from the randomised, open-label, contro...

Pediatric leukemia 'super drug' could be developed…

Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published ...

Researchers uncover new mechanism of gene regulati…

Genes contain all the information needed for the functioning of cells, tissues, and organs in our body. Gene expression, meaning when and how are the genes being read and...

AstraZeneca announces organisational changes

AstraZeneca is today announcing organisational changes to support continued scientific innovation and commercial success in the main therapy areas as the Company enters a...

Tumors backfire on chemotherapy

Some patients with breast cancer receive chemotherapy before the tumor is removed with surgery. This approach, called 'neoadjuvant' therapy, helps to reduce the size of t...

Sandoz and Pear Therapeutics announce US launch of…

Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O(TM) for patients with Opioid Use Disorder (OUD). reSET-...

Boehringer Ingelheim initiates a collaborative par…

Science 37, an industry leader in virtual clinical trials, and Boehringer Ingelheim announced a technology enterprise collaboration agreement that will support Boehringer...

Pfizer initiates phase 2b/3 clinical trial for PF-…

Pfizer Inc. (NYSE: PFE) announced the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to s...

Stopping cancer from recruiting immune system doub…

Cancerous tumors trick myeloid cells, an important part of the immune system, into perceiving them as a damaged part of the body; the tumors actually put myeloid cells to...

EVENITY™ (romosozumab) receives approval in Japan …

Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY™ ...